Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.

about

Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.

Item

http://www.wikidata.org/entity/Q47097708

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Factor Xa inhibition by rivaro ...... ly reduce thrombin generation.

@en

Factor Xa inhibition by rivaro ...... ly reduce thrombin generation.

@nl

type

Item

label

Factor Xa inhibition by rivaro ...... ly reduce thrombin generation.

@en

Factor Xa inhibition by rivaro ...... ly reduce thrombin generation.

@nl

prefLabel

Factor Xa inhibition by rivaro ...... ly reduce thrombin generation.

@en

Factor Xa inhibition by rivaro ...... ly reduce thrombin generation.

@nl

P1476

Factor Xa inhibition by rivaro ...... tly reduce thrombin generation

@en

P2093

Rie Sugawara

http://www.w3.org/2001/XMLSchema#string

Toshihiko Ishimitsu

http://www.w3.org/2001/XMLSchema#string

Yutaka Yonezawa

http://www.w3.org/2001/XMLSchema#string

P2860

Structure and biology of tissue factor pathway inhibitor

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.

The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va

Laboratory markers of coagulation activation.

Venous thrombosis associated with gene deletion of tissue factor pathway inhibitor.

P304

79-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13429

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shigeo Horinaka

P577

2017-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28888219

http://www.w3.org/2001/XMLSchema#string

P932

5736851

http://www.w3.org/2001/XMLSchema#string